Quarterly report pursuant to Section 13 or 15(d)

Related Party Transactions (Details Narrative)

v3.19.1
Related Party Transactions (Details Narrative) - USD ($)
3 Months Ended
Dec. 31, 2018
Dec. 19, 2018
Nov. 27, 2018
Oct. 26, 2018
Oct. 17, 2018
May 25, 2018
Dec. 31, 2018
Dec. 31, 2017
Sep. 30, 2018
Defined Benefit Plan Disclosure [Line Items]                  
Accrued payroll and benefits due to officers $ 200,635           $ 200,635   $ 180,025
Consulting fees             240,959 $ 112,803  
Mick Ruxin [Member]                  
Defined Benefit Plan Disclosure [Line Items]                  
Salary and wages             44,361    
Jeffrey Busch [Member]                  
Defined Benefit Plan Disclosure [Line Items]                  
Salary and wages             7,500    
Investor Representative [Member]                  
Defined Benefit Plan Disclosure [Line Items]                  
Consulting fees             40,000    
Scott VanderMeer [Member]                  
Defined Benefit Plan Disclosure [Line Items]                  
Consulting fees             $ 36,075    
Employment Agreement [Member] | Dr. Michael Ruxin [Member]                  
Defined Benefit Plan Disclosure [Line Items]                  
Employment agreement, description           The Company entered into an employment agreement (the "Ruxin Agreement") with Dr. Ruxin under which he will serve as Chief Executive Officer of the Company. The term of the Ruxin Agreement was effective as of May 25, 2018, continues until May 25, 2023 and automatically renews for successive one-year periods at the end of each term until either party delivers written notice of their intent not to renew at least 60 days prior to the expiration of the then effective term. Under the terms of the Ruxin Agreement, Dr. Ruxin will receive an annual salary of $250,000. He is eligible to receive a cash bonus of up to 100% of his base salary. The bonus shall be earned upon the Company's achievement of performance targets for a fiscal year to be mutually agreed upon by Dr. Ruxin and the board or a committee thereof. Additionally, following the adoption by the Company of an equity compensation plan and subject to approval of the board or a committee thereof, Dr. Ruxin shall receive (i) a one-time restricted stock unit award having a fair value of approximately $100,000 and which shall vest over a five year period following the date of grant and (ii) an option to purchase ten percent (10%) of the outstanding shares of the Company (calculated on the date of grant), which shall vest over a five-year period following the date of grant and expire on the tenth anniversary of the date of grant.      
Annual base salary           $ 250,000      
Fair value of restricted stock vested           $ 100,000      
Employment Agreement [Member] | Mr. Busch [Member]                  
Defined Benefit Plan Disclosure [Line Items]                  
Employment agreement, description           The Company entered into an employment agreement (the "Busch Agreement") with Mr. Busch under which he will serve as Executive Chairman of the Company. The term of the Busch Agreement was effective as of May 25, 2018, continues until May 25, 2023 and automatically renews for successive one-year periods at the end of each term until either party delivers written notice of their intent not to renew at least 60 days prior to the expiration of the then effective term. Under the terms of the Busch Agreement, Mr. Busch will receive an annual salary of $30,000, which amount shall be automatically increased to $120,000 on the first anniversary of the date of the Busch Agreement. He is eligible to receive a discretionary cash bonus at the option of the board based on their evaluation of his performance of duties and responsibility. Additionally, following the adoption by the Company of an equity compensation plan and subject to approval of the board or a committee thereof, Mr. Busch shall receive (i) a one-time restricted stock unit award having a fair value of approximately $100,000 and which shall vest over a five year period following the date of grant and (ii) an option to purchase ten percent (10%) of the outstanding shares of the Company (calculated on the date of grant), which shall vest over a five-year period following the date of grant and expire on the tenth anniversary of the date of grant.      
Annual base salary           $ 30,000      
Fair value of restricted stock vested           100,000      
Employment Agreement [Member] | Mr. Busch [Member] | First Anniversary [Member]                  
Defined Benefit Plan Disclosure [Line Items]                  
Annual base salary           120,000      
Consulting Agreement [Member] | Investor [Member]                  
Defined Benefit Plan Disclosure [Line Items]                  
Annual amount payable           $ 160,000      
Purchase Agreement [Member] | Jeffrey Busch [Member] | Series A Preferred Stock [Member]                  
Defined Benefit Plan Disclosure [Line Items]                  
Number of stock sold   25,000 12,000   2,500        
Proceeds from sale of stock   $ 25,000 $ 12,000   $ 2,500        
Purchase Agreement [Member] | Henry Cole [Member] | Series A Preferred Stock [Member]                  
Defined Benefit Plan Disclosure [Line Items]                  
Number of stock sold         20,000        
Proceeds from sale of stock         $ 20,000        
Purchase Agreement [Member] | Dr. Rajesh Shrotriya [Member] | Series A Preferred Stock [Member]                  
Defined Benefit Plan Disclosure [Line Items]                  
Number of stock sold 50,000     100,000          
Proceeds from sale of stock $ 50,000     $ 100,000